by Jordana Choucair | Jan 14, 2022 | Opioid/Substance Use Disorders
An article in Treatment Magazine describes the need for value-based substance use disorder treatment, highlighting insights from Greg Williams, Third Horizon Strategies Managing Partner and Manager of the Alliance for Addiction Payment Reform (Alliance). The article...
by Jordana Choucair | Jan 12, 2022 | Opioid/Substance Use Disorders
A new study published in JAMA Network Open found that the annual opioid overdose death rate per 100,000 persons for adults aged 55 and older increased substantially since 2019. Furthermore, rates varied substantially by sex and by race and ethnicity over time....
by Jordana Choucair | Dec 30, 2021 | Opioid/Substance Use Disorders
U.S. Bankruptcy Judge Robert Drain has extended temporary protections against opioid-related litigation for the Sackler family members who own Purdue Pharma until February 1. In September, Drain had approved Purdue’s reorganization plan and underlying settlement,...
by Jordana Choucair | Dec 20, 2021 | Opioid/Substance Use Disorders
A new HHS Office of the Inspector General report found that less than 16 percent of more than one million Medicare beneficiaries diagnosed with opioid use disorder in 2020 received medication to treat the condition. Furthermore, less than one third of those who...
by Jordana Choucair | Dec 17, 2021 | Opioid/Substance Use Disorders
A federal court judge has reversed the Purdue Pharma bankruptcy plan. A provision in the plan grants immunity to some of the Sacklers as well as hundreds of their associates from future lawsuits, even though — unlike Purdue — they did not file for bankruptcy...
by Jordana Choucair | Dec 9, 2021 | Opioid/Substance Use Disorders
AbbVie Inc.’s Allergan unit will pay up to $200 million to New York state and two counties to settle claims that it allowed opioid painkillers to overwhelm the region. State Attorney General Letitia James said that the funding will go toward opioid treatment,...
Recent Comments